Opendata, web and dolomites

D2P SIGNED

Diabeloop to Patients: An Artificial Pancreas solution to improve the balance, safety and autonomy of 20 million people

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 D2P project word cloud

Explore the words cloud of the D2P project. It provides you a very rough idea of what is the project "D2P" about.

glucose    innovation    artificial    foreign    stressful    dblg1    healthy    storage    upgrade    netherlands    telemonitoring    diabetes    core    daily    validate    regulating    begin    generation    causes    regulation    half    pancreas    exchange    blindness    autoimmune    model    producing    patients    million    personalised    healthcare    hypoglycaemia    basis    fainting    appropriate    alleviate    cells    specificities    situations    optimisation    countries    delivered    monitoring    clinicians    diabeloop    renal    anyone    algorithms    solution    secured    severe    worldwide    amputations    identification    professional    loop    breakthrough    t1d    device    adjustments    coma    market    complementary    calculate    intelligence    continuous    seizures    reduce    complications    function    diseases    countless    goals    made    burden    first    pump    physiological    industrialisation    day    closed    telemedicine    connected    sweden    destruction    handset    patient    integrates    beta    france    customisation    20    performances    dose    insulin    models    age    data    periods    automatically    treatment    people    sensor    hosting    suggest    hyperglycaemia    components    mimic    heart    adoption    death   

Project "D2P" data sheet

The following table provides information about the project.

Coordinator
DIABELOOP 

Organization address
address: 155-157 COURS BERRIAT
city: GRENOBLE
postcode: 38028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙190 €
 EC max contribution 1˙955˙233 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DIABELOOP FR (GRENOBLE) coordinator 1˙955˙233.00

Map

 Project objective

20 million people worldwide are affected by type 1 diabetes (T1D), an autoimmune condition leading to the destruction of beta cells of the pancreas producing insulin. T1D causes severe complications: short terms - seizures and fainting that could result in coma or even death; long terms - blindness, amputations, renal failure, heart diseases. T1D can occur to anyone and half of the cases begin before age 20. T1D patients have to manage their diabetes on a daily basis, facing countless stressful situations.

Diabeloop’s “artificial pancreas” solution aims to mimic the glucose regulating function of a healthy pancreas. The core of our “artificial pancreas” solution is an artificial intelligence: algorithms based on physiological models continuously calculate the most appropriate and personalised dose of insulin. Insulin is then automatically delivered to the patient. Diabeloop goals are to reduce hypoglycaemia and hyperglycaemia periods, alleviate the day-to-day burden and avoid long-term complications.

Diabeloop’s first generation solution (DBLG1) is integrated in a closed-loop system made of three components: a continuous glucose monitoring sensor, a connected insulin pump, and a handset hosting algorithms and controlling the pump. Diabeloop’s solution integrates a telemedicine program through highly secured data exchange, storage and healthcare professional identification. Clinicians may access the patients’ data and suggest treatment adjustments as necessary, for an improved system customisation and long-term regulation. During the phase 2 project, we scale up and target a European adoption of our breakthrough innovation. We focus on France, the Netherlands and Sweden, 3 countries with complementary specificities to validate our model: adaptation of the device to foreign market, optimisation of performances, telemonitoring upgrade and industrialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "D2P" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "D2P" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Cortx (2019)

Intelligent debt recovery platform.

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More